Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Email this article to a friend

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Mark J McKeage*, Michael B Jameson, Ramesh K Ramanathan, Joseph Rajendran, Yongchuan Gu, William R Wilson, Teresa J Melink and N Simon Tchekmedyian

BMC Cancer 2012, 12:496  doi:10.1186/1471-2407-12-496

Fields marked * are required

Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive BMC Cancer's emails?